On Monday, the United States Food and Drug Administration (FDA) was sued for allegedly withholding records detailing the off-label use of hormone treatments, such as puberty blockers, by underaged children.
Fox News reports that the lawsuit was filed by Stephen Miller’s America First Legal (AFL) group, which had previously made a Freedom of Information Act (FOIA) request back in September regarding the use of such hormone drugs on children under the Biden Administration. After the FDA refused to respond to the request, AFL filed their lawsuit.
“The FOIA’s purpose is to ensure an informed citizenry, vital to the functioning of a democratic society, needed to check against corruption and to hold the governors accountable to the governed,” the lawsuit states. “By failing to comply with the FOIA, the FDA is depriving AFL and the public of vital information needed to evaluate FDA’s compliance with the law regarding the off-label use of puberty blockers and cross-sex hormones on children.”
Hormone treatments such as puberty blockers and cross-sex hormones, often incorrectly referred to as “gender-affirming care,” have been widely condemned as child abuse, essentially turning impressionable pre-pubescent children into living experiments. Children who may suffer from the mental illness of transgenderism, formally known as “gender dysphoria,” often attempt to seek such treatments in order to reinforce their own delusions.
However, such treatments can lead to numerous harmful lifelong effects, including sterilization, weight gain, blood clots, high blood pressure, and depression. Studies have shown that going through treatments, including genital mutilation surgery, have no impact on the overall suicide rate among people who believe they are transgender.
An example of such a drug is gonadotropin-releasing hormone (GnRh) agonists, to which the FDA did recently add a warning label notifying potential users of the risk of pseudotumor cerebri, a condition that mimics the symptoms of a brain tumor to the point that one can suffer vision loss as a result. According to AFL’s FOIA request, the FDA has approved GnRh agonists for use in chemical castration, as well as treating precocious puberty, despite the fact that they have not been approved for use as puberty blockers.
“The recent allegations from a whistleblower at the Washington University Transgender Clinic at St. Louis Children’s Hospital is just the latest obvious warning of the dangerous experimentation on children with off label drugs like Lupron and other puberty blockers and cross-sex hormones,” said Ian Prior, a senior advisor for AFL. “Yet, while European nations are pulling back on these dangerous practices, America is putting them into warp speed with the backing of the Biden Administration. The American people deserve to know exactly what its government is doing. And if we have to take the FDA to court to find out, so be it.”